



Dr Adrian Attard Trevisan

Perth, Australia & Malta – 27 March 2019 – Neurotech International Limited (ASX:NTI) (Neurotech or the Company) announces that it has become aware of an article in the Times of Malta newspaper concerning the qualifications of its strategic adviser, Dr Adrian Attard Trevisan.

The article asserts that Dr Attard Trevisan does not have a PhD in Neuroscience from University College London, that he has misled the public as having credentials as a PhD in Neuroscience, that Dr Attard Trevisan has admitted that he does not have a PhD from University College London and that Dr Attard Trevisan only has a PhD in Human Physiology from the University of Milan.

The assertions refer to Dr Attard Trevisan's conduct during the period 2012 to 2015.

The article, and the information it contained, were deeply disappointing to Neurotech, its Board and management.

Dr Attard Trevisan ceased to be an employee of Neurotech in April 2016 and resigned as a Director of the company in June 2018. He no longer has any role with Neurotech.

Dr Attard Trevisan resumed providing specific advisory services to the Company as announced on 20 December last year. His role has been a limited one and has now been terminated.

Neurotech's flagship product Mente is the result of much more than the work of one person. Neurotech's dedicated Mente team has worked for many years to create, refine and improve the device and its therapeutic outcomes – and that work continues today, and into the future.

Mente's personalised neurofeedback therapy is a form of brain training that is backed by extensive scientific literature.

As a company, we stand behind the peer-reviewed science of Mente, and the results it is delivering for children with autism spectrum disorder.

The positive outcomes that Mente enables for children with autism have been validated in a double-blind independent clinical trial in the US and many parent testimonials. The device has also achieved CE medical certification.

Neurotech's Scientific Advisory Board, comprising highly-qualified professionals in the fields of psychology, psychiatry and neurotherapy, continues to provide strategic counsel to our team in their ongoing work to improve the Mente product and the benefits it delivers for families.

The company is under new operational leadership in 2019. We have recently announced we will focus on enabling Mente through clinics, to ensure it is recommended to children who can really benefit from this technology, and we are working to implement feedback from clinics, partners

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 225 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

and parents to reduce the entry price of Mente and implement a low-risk shared-success subscription model to make it more accessible to families.

We are confident in our offering, and our Mente team continues to focus on the goal of helping to improve the lives of families working with autism and neurodevelopmental disorders.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism.

Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated delta band brain activity.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420